The endometriosis market was valued at USD 691.55 Million in 2024 driven by innovations in treatment options across the 8 major markets. It is expected to grow at a CAGR of 5.21% during the forecast period of 2025-2034 and attain a market value of USD 1149.20 Million by 2034.
Base Year
Historical Year
Forecast Year
The rising prevalence of endometriosis is driving demand for innovative treatment options, including hormone therapies and non-invasive pain management solutions, thereby, boosting market growth.
Surge in clinical trials and research initiatives is one of the notable market trends. For instance, in March 2023, a significant clinical trial was funded to investigate a new non-hormonal therapy for endometriosis. This highlights the market's focus on addressing unmet needs through innovative approaches, driving growth in treatment options.
North America is estimated to lead the market due to advanced healthcare infrastructure, substantial investments in R&D, and increased awareness campaigns, solidifying its dominance in the forecast period.
Endometriosis is a persistent condition, characterized by the growth of tissue like the uterine lining outside the uterus, leading to pain and potential infertility, The market for endometriosis treatment is expanding due to the increasing incidence of the condition, which affects approximately 10% of the women worldwide. Key trends contributing to this growth include heightened investment in clinical trials and the development of non-hormonal treatment options. This awareness of the condition and ongoing innovation in therapeutic solutions will significantly drive the market in the forecast period.
Rising Prevalence of Endometriosis Drives Market Growth
The rising prevalence of endometriosis has significantly contributed to the growth of the market. As reported by the World Health Organization (WHO), approximately 10% (190 million) of reproductive-age women and girls are affected by this condition globally. This alarming statistic highlights the urgent need for innovative therapies and comprehensive treatment options, thereby driving market expansion and investment opportunities in the healthcare sector.
Several trends and developments are being observed in the market to enhance the current situation. Some of the noteworthy trends are as follows:
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Class
Market Breakup by Drug Class
Market Breakup by Route of Administration
Market Breakup by Treatment Type
Market Breakup by Distribution Channel
Market Breakup by Region
Market Share by Route of Administration Set to Witness Significant Growth
Based on the route of administration the market is divided into oral, injectables, and others. Among these, the oral route is expected to dominate the market. Innovative oral medicines, such as Elagolix, Danazol, etc, with their potential for convenience, patient compliance, and cost-effectiveness, account for a significant share of the overall pharmaceutical landscape. This segment is poised for significant expansion during the forecast period, largely due to increasing awareness and demand for patient-friendly treatment options.
Based on region, the market report covers the United States, United Kingdom, Germany, France, Italy, Spain, Japan, and India. Among these, the United States is expected to dominate the market due to advanced technology, strong consumer demand, and substantial investments in innovation. This region is poised for future growth with increasing adoption of digital solutions, and rising health consciousness among consumers. Additionally, the government initiatives in healthcare infrastructure enhance competitiveness, making this region a key driver of market expansion in the forecast period.
The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Founded in 1863 and headquartered in Leverkusen, Germany, Bayer AG is a global life sciences company. For endometriosis, Bayer has developed Visanne (dienogest), a progestin-only oral treatment approved for managing endometriosis symptoms by reducing pelvic pain and lesions.
Established in 1849, Pfizer is based in New York City, USA. The company has developed Depo-Provera (medroxyprogesterone acetate), primarily a contraceptive, but also used for treating endometriosis-related symptoms such as pelvic pain.
AbbVie, founded in 2013 and headquartered in North Chicago, Illinois, USA, is renowned for its biopharmaceuticals. The company developed Orilissa (elagolix), a non-hormonal oral medication for treating moderate to severe endometriosis-related pain by inhibiting estrogen production.
Founded in 1999 and headquartered in Cambridge, UK, AstraZeneca is a major pharmaceutical player. The company developed Zoladex (goserelin), a GnRH agonist used to manage symptoms of endometriosis by suppressing estrogen levels and reducing inflammation and pain.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other companies include ObsEva, Teva Pharmaceuticals, Astellas Pharma Inc., and Eli Lilly and Company.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Drug Class |
|
| Breakup by Route of Administration |
|
| Breakup by Treatment Type |
|
| Breakup by Distribution Channel |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,969
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share